|
|
||||||||||||||||||||||||||||||||||||||||||||||||||
By The Online Investor Staff, updated Sat., May. 30, 6:46 AM
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
Secondary Stock Offerings| This Slide: #22 of 25 |
Slide #22. VolitionRx Limited — Secondary Offering
Company:
VolitionRx Limited (AMEX:VNRX)
Date announced:
5/19/2020
Shares Offered:
4,365,000
Date of Pricing:
5/20/2020
Price Per Share:
$2.75
Secondary Offering Details:
VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Volition intends to grant the underwriters a 30-day option to purchase additional shares of its common stock sold in the offering, to cover overallotments, if any. All shares of common stock in the offering are being offered by Volition. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 5/20- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company that applies its NucleosomicsTM platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today the pricing of its previously announced underwritten public offering. Volition is offering 4,365,000 shares of common stock, par value $0.001 per share, at a price to the public of $2.75 per share. In connection with the offering, Volition has also granted the underwriters a 30-day option to purchase up to an additional 654,750 shares of its common stock offered in the public offering, at the same public offering price per share, to cover overallotments, if any. All shares of common stock in the offering are being offered by Volition.
VolitionRx is a life sciences company developing blood tests to help diagnose a range of cancers and other diseases. Co.'s tests are based on the science of Nucleosomics®, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. Using Co.'s Nucleosomics technology, Co. is developing epigenetic Nu.Q assays, which are designed to detect the level and structure of nucleosomes in blood. Co. is developing blood-based tests for prevalent cancers focusing on colorectal cancer, lung cancer, prostate cancer and pancreatic cancer.
Open the VNRX Page at The Online Investor »
|
|||||||||||||||||||||
Open the VNRX Page at The Online Investor (in a new window) »
|
|
Avg. Broker Rec.
|
Strong Buy (4.00 out of 4) 81st percentile
(ranked higher than approx. 81% of all stocks covered)
Based on Zacks ABR data; powered by Xignite |
Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2020, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.